MedTrace Logo

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

NCT06792214 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2025-01-24

No results posted yet for this study

Summary

The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.

Conditions

  • SARS CoV-2 Post-Acute Sequelae

Interventions

DRUG

Nirmatrelvir/ritonavir

Paxlovid PO BID for 5 days + standard of care

DRUG

Remdesivir

Veklury IV daily for 5 days + standard of care

Sponsors & Collaborators

  • Unity Health Toronto

    collaborator OTHER

  • Kingston Health Sciences Centre

    collaborator OTHER

  • Niagara Health System

    collaborator OTHER

  • Mount Sinai Hospital, Canada

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-03
Primary Completion
2026-01-31
Completion
2027-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06792214 on ClinicalTrials.gov